GODAVARIB
Godavari Biorefineries share price & financials
- Price
- ₹294.05
- Market cap
- ₹1.2k Cr
- Sector
- Fast Moving Consumer Goods
- Calls analysed
- 6
Godavari Bioref. Q4 FY26
What went well
- FY26 total income increased by 6% year-on-year to INR2,000 crores.
- FY26 EBITDA grew 15.8% to INR139 crores, with margins stabilizing at 7%.
- Q4 FY26 Profit After Tax (PAT) showed a strong recovery, reaching INR52.9 crores from INR8.3 crores in Q3 FY26.
What to watch
- FY26 Profit After Tax was a modest INR3.5 crores, though a turnaround from a loss in FY25.
- EBITDA margins remained under pressure during parts of FY26 due to elevated feedstock costs.
What Godavari Biorefineries Limited does
Godavari Biorefineries operates an integrated biorefinery that crushes sugarcane to produce sugar, ethanol and bagasse-based cogeneration power, and separately processes molasses and sugarcane derivatives into bio-based specialty and non-specialty chemicals (such as ethyl acetate, acetic acid, extra neutral alcohol and acetaldehyde) sold to personal care, cosmetics, food, fragrance, fuel, paints, agrochemical and pharmaceutical customers. It also markets packaged sugar, jaggery, salt and spices under its Jivana consumer brand, sells surplus power to the grid, and pursues early-stage drug-discovery research (including an oncology molecule and an antiviral platform) through in-house R&D and a US subsidiary. The company is building a new grain/maize-based ethanol distillery to add fungible ethanol capacity.
Segments
- Integrated Sugar, Co-generation & Ethanol
- Bio-Based Chemicals
- Manufacturing facilities
- 2 (Sameerwadi, Karnataka + Sakarwadi, Maharashtra)
- Market position
- Among India's largest producers of ethanol by volume at a single location
- R&D facilities
- 3 DSIR-registered R&D facilities with 50+ researchers and scientists
- Jivana brand retail reach
- 7,500+ stores
- New ethanol capacity under construction
- 200 KLPD grain/maize-based distillery adding ~60 million litres/year capacity
- Drug-discovery subsidiary
- Sathgen Therapeutics (US subsidiary for global IP creation and out-licensing)
Guidance record · Q4 FY26
what the last two calls moved 8 tracked 1 delivered 0 missed 7 open- R&D Milestone delivered said Q4 FY25 Promised: Safety trial is expected to be complete in Q2 FY26. Q4 FY26: Remains achieved. Company confirms safety trials are complete and is now preparing application to CDSCO for efficacy trials.
- Capacity Commissioning Timeline delayed said Q3 FY25 Promised: Targeting for commissioning from Q4 of the coming financial year which is H2 FY26. Q4 FY26: Further delayed. Commissioning trials now expected in June 2026 (Q1 FY27), pushed from the previous target of March/April 2026.
- EBITDA Growth on track said Q4 FY25 Promised: Targeting an increase in EBITDA by about 3x of FY25 numbers by FY29 (approx INR 360 crores). Q4 FY26: FY26 EBITDA grew 15.8% YoY to INR 139 crores, a step towards the FY29 goal of ~INR 360 crores. Growth drivers (chemicals, new distillery) are progressing.
All 8 tracked — every revision, and every one management stopped mentioning.
Open the guidance ledgerQuarterly results
Q1 FY27: revenue up 3.6%, net profit down 23.5% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 316 | 445 | 576 | 523 | 423 +34% | 457 +3% | 562 −2% | 542 +4% |
| EBITDA | -34 | 37 | 110 | 5 | -9 +74% | 43 +16% | 86 −22% | -2 −140% |
| Net profit | -76 | 6 | 70 | -17 | -43 +43% | 8 +33% | 52 −26% | -21 −24% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −20.0% 1Y
1Y: ₹292.18 on 10 Sept 2025 → ₹233.65. High ₹334.9 (23 Apr 2026), low ₹232.25 (14 Oct 2025).
How the price took the results
close before → close after
- Q4 FY26
- −3.1%
- 26 May
- Q3 FY26
- +2.3%
- 26 Feb
- Q2 FY26
- +3.7%
- 14 Nov
The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.
Financials, as filed
Revenue grew 6.0% a year over 1 year, FY25 to FY26. Operating margin widened to 6.4%.
| Year ending | FY25 | FY26 |
|---|---|---|
| Revenue | ₹1.9k Cr | ₹2.0k Cr |
| Operating profit | ₹100 Cr | ₹125 Cr |
| Operating margin | 5.4% | 6.4% |
| Interest | ₹72 Cr | ₹48 Cr |
| Depreciation | ₹50 Cr | ₹54 Cr |
| Net profit | ₹-27 Cr | ₹0 Cr |
| Net margin | -1.5% | 0.0% |
| Cash from operations | ₹-1 Cr | ₹173 Cr |
| Free cash flow | ₹-73 Cr | ₹8 Cr |
| ROCE | 6.0% | 6.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹42 Cr | ₹42 Cr | ₹42 Cr | ₹42 Cr | ₹51 Cr | ₹51 Cr |
| Reserves | ₹416 Cr | ₹432 Cr | ₹442 Cr | ₹452 Cr | ₹674 Cr | ₹722 Cr |
| Borrowings | ₹564 Cr | ₹634 Cr | ₹739 Cr | ₹655 Cr | ₹493 Cr | ₹525 Cr |
| Other liabilities | ₹417 Cr | ₹625 Cr | ₹517 Cr | ₹838 Cr | ₹246 Cr | ₹730 Cr |
| Total liabilities | ₹1.4k Cr | ₹1.7k Cr | ₹1.7k Cr | ₹2.0k Cr | ₹1.5k Cr | ₹2.0k Cr |
| Fixed assets | ₹706 Cr | ₹666 Cr | ₹866 Cr | ₹849 Cr | ₹860 Cr | ₹884 Cr |
| Capital work in progress | ₹9 Cr | ₹50 Cr | ₹17 Cr | ₹29 Cr | ₹81 Cr | ₹130 Cr |
| Investments | ₹14 Cr | ₹14 Cr | ₹16 Cr | ₹16 Cr | ₹0 Cr | ₹16 Cr |
| Other assets | ₹711 Cr | ₹1.0k Cr | ₹842 Cr | ₹1.1k Cr | ₹522 Cr | ₹999 Cr |
| Total assets | ₹1.4k Cr | ₹1.7k Cr | ₹1.7k Cr | ₹2.0k Cr | ₹1.5k Cr | ₹2.0k Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, the public added +4.35 pp while DIIs trimmed −3.96 pp. The shareholder count shrank 7% to 89,419.
- Promoters
- 63.3%
- FIIs
- 0.2%
- DIIs
- 10.0%
- Public
- 26.4%
Since Jun 2025
- Public +4.35 pp
- DIIs −3.96 pp
- FIIs −0.41 pp
How it drifted, 7 quarters
Over this window the public went from 20.7% to 26.4% — +5.8 pp.
Ownership split by quarter, oldest first. Dec '24: Promoters 63.3%, FIIs 1.1%, DIIs 14.9%, Public 20.7%.Mar '25: Promoters 63.3%, FIIs 1.0%, DIIs 14.2%, Public 21.6%.Jun '25: Promoters 63.3%, FIIs 0.6%, DIIs 14.0%, Public 22.1%.Sep '25: Promoters 63.3%, FIIs 0.6%, DIIs 12.0%, Public 24.1%.Dec '25: Promoters 63.3%, FIIs 0.9%, DIIs 11.2%, Public 24.7%.Mar '26: Promoters 63.3%, FIIs 1.0%, DIIs 10.4%, Public 25.3%.Jun '26: Promoters 63.3%, FIIs 0.2%, DIIs 10.0%, Public 26.4%.
Who is on the register
Named in the Jun 2026 filing
Every holder of Godavari Biorefineries Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Somaiya Agencies Pvt Ltd | 17.30% | unchanged |
| Sakarwadi Trading Company Private Limited | 11.76% | unchanged |
| Samir Shantilal Somaiya | 10.79% | unchanged |
| Lakshmiwadi Mines And Minerals Private Limited | 10.79% | unchanged |
| Sindhur Construction Pvt Ltd | 5.73% | unchanged |
| ICICI Prudential ELSS Tax Saver Fund Mutual fund | 3.97% | unchanged |
| HDFC Mutual Fund - HDFC Manufacturing Fund Mutual fund | 3.66% | −0.34 pp |
| Zenith Commercial Agencie S Private Limited | 1.82% | unchanged |
| Bank Of India Small Cap Fund Mutual fund | 1.26% | unchanged |
| Jasmine Trading Company Private Limited | 1.20% | unchanged |
| K J Somaiya And Sons Private Limited | 1.16% | unchanged |
| Filmedia Communication Systems Private Limited | 0.93% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Mutual funds in GODAVARIB
Filings to Jul 2026
0 new, 0 added, 0 trimmed, 0 sold out — net +0.00 L shares (+0.0%).
- Held by funds
- ₹47 Cr
- 1 schemes
- Biggest holder
- HDFC Manufacturing Fund
- ₹47 Cr · 0.5% of that fund
| Scheme | Holding | Last month | Held since |
|---|---|---|---|
| HDFC Manufacturing Fund HDFC Mutual Fund | ₹47 Cr | held | Oct '24 |
HDFC, Nippon India and SBI schemes, from their monthly disclosures. Changes are counted in shares, so a price move never looks like buying or selling.
Mutual funds Jul 2026
0 added, 0 trimmed — net 0 shares (+0.0%)
- Funds are sitting on
- -2%
- vs est. average cost
- Held by funds
- ₹47 Cr
- 1 schemes · ≈ 4.4% of the company
Shares held by these funds +33%
Oct '24 18.10 L shares Jul '26
All earnings calls (6)
Read the Q4 FY26 call →Learn to analyse Godavari Biorefineries Limited
Guides on how to read this kind of business and the numbers that matter.